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Abstract BACKGROUND: Emotionally unstable personality disorder (EUPD) is a chal-
lenging condition with a prevalence of 20% in inpatient services. Psychotherapy 
is the preferred treatment; nevertheless, off-license medications are widely used. 
OBJECTIVES: To identify socio-demographics, clinical and service-delivery char-
acteristics of people with EUPD admitted to inpatient services between 1st January 
2017 and 31st December 2018. 
METHODS: A retrospective review using data from patients’ records. Individuals, 
age 18–65 were included. Statistical analysis was conducted by the Mann-
Whitney-Wilcoxon test and Chi-squared test with Yates’s continuity correction.
RESULTS: Of 1646 inpatients, 201 (12.2%); had the diagnosis of EUPD; 133 (66.0%) 
women, 68 (44.0%). EUPD was significantly (P < .001) more prevalent in women 
(18.2%) than men (7.4%). EUPD patients were significantly (P < .001) younger 
(32.2 years) than patients without EUPD (46 years), and had significantly (P < .001) 
more admissions (1.74) than patients without EUPD (1.2 admission). 70.5% 
of patients had one and 17.0% two Axis-I psychiatric co-morbidities. Substance use 
was significantly (P < .001) more often in men (57.3%) than in women (28.5%). 
Significantly (P = 0.047) more women (68.4%) than men (53.0%) reported sexual 
abuse. 87.5% used polypharmacy. Antidepressants were significantly (P = 0.02) 
often prescribed to women (76.6%) than men (69.1%). Significantly (P = 0.02) 
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more women (83.5%) than men (67.6%) were on 
antipsychotics. 57.2% of the patients were on anxiolytics, 
40.0% on hypnotics and 25.8% on mood stabilisers.
CONCLUSION: EUPD is a complex condition with 
widespread comorbidity. The term EUPD, Borderline 
Personality Disorder is unsuitable, stigmatising and too 
simplistic to reflect the nature, gravity and psychopa-
thology of this syndrome.
INTRODUCTION
EUPD has an estimated prevalence of 1% to 2% in the 
general population; and 10% in community psychiatric 
services (APA, 2001). Data on the prevalence of EUPD 
in inpatient services differ; some studies (Doering, 
2019) estimate it between 9% and 14%, however, others 
(Gunderson et al. 2018) report higher figures between 
15% and 28%. This disorder is largely diagnosed 
in women, with an estimated female to male ratio 
of 3:1(Oldham, 2005).
According to ICD 10 (WHO, 1992), the key feature 
of the EUPD is emotional instability; in addition, 
the patient's own self-image, and internal prefer-
ences (including sexual) are often disturbed. There 
are usually chronic feelings of emptiness. A liability 
to become involved in intense and unstable relation-
ships may cause repeated emotional crises and may be 
associated with excessive efforts to avoid abandonment 
and a series of suicidal threats or acts of self-harm. The 
diagnosis of EUPD in the Statistical Manual of Mental 
Disorders, Fifth Edition (APA, 2013), is based on 
the evidence of  (1) a pervasive pattern of instability 
of  interpersonal relationships, self-image, and affects, 
and (2) marked impulsivity beginning by early adult-
hood and present in a variety of contexts, including 
frantic efforts to avoid real or imagined abandonment,; 
unstable and intense relationships; identity distur-
bance; impulsivity that is potentially self-damaging in 
at least two of the following areas such as spending, sex, 
substance abuse, reckless driving, binge eating; recur-
rent suicidal gestures or threats, or self-mutilation; 
marked mood reactivity; chronic feelings of emptiness; 
frequent displays of inappropriate or intense anger; and 
stress-related paranoid ideation or severe dissociative 
symptoms.
The aetiology of EUPD incorporates the concep-
tion of a biological predisposition along with psycho-
logical and environmental factors. There is a sufficient 
body of evidence of genetic factors contributing to the 
progress of EUPD (Torgersen et al. 2008). Patients 
with EUPD report many negative life events, including 
a history of childhood sexual or/and physical abuse 
(Paris, 2007). Childhood sexual abuse is an important 
risk factor for EUPD and predicts more severe clinical 
presentation and poorer prognosis (de Aquino Ferreira, 
et al. 2018). Therefore, an interaction between biolog-
ical and psychosocial factors will probably provide the 
best explanation of how the EUPD develops (Gabbard, 
2005).
People with EUPD are at an increased risk of suicide 
(Cheng et al. 1997), with up to 85% engaging in 
attempting suicidal behaviours (Timäus et al. 2019). 
The rate of completed suicide has been estimated 
to be approximately 10% (Oldham, 2006), however, 
recent data (Temes et al. 2019) report lower, around 
6% of suicide rate. There is a well-documented associa-
tion between EUPD and other psychiatric conditions 
(Wetterborg et al. 2015). Because of a considerable 
overlap between EUPD and mood disorders, it has 
been suggested that EUPD should be classified in the 
context of mood disorders. Likewise, its association 
with past trauma, and similarities of its presentation 
with post-traumatic stress disorder (PTSD), has led 
some to  suggest that EUPD should be regarded as 
a form of delayed PTSD (Yen & Shea, 2001). 
In terms of management of the EUPD, in the United 
Kingdom, no medication is particularly licensed for 
EUPD, and the National Institute for Health and 
Clinical Excellence (NICE) recommends medication 
only for co-morbid mental disorders (NICE, 2009). The 
American Psychiatric Association’s practice guidelines 
(APA, 2005) in line with NICE recommend psycho-
therapy as the main treatment; however, in contrast 
to  NICE, APA considers pharmacotherapy as an 
adjunctive component of treatment that targets state 
symptoms during periods of acute decompensation. 
Earlier findings (Lieb et al. 2010) suggested that anti-
depressants such as selective serotonin reuptake inhibi-
tors (SSRI’s) and serotonin and noradrenalin reuptake 
inhibitors (SNRI’s) are being effective for treatment 
of  aggression, irritability, depression and self-mutila-
tion. Also, drugs such as mood stabilisers (MS’s) and 
second-generation antipsychotics (SGAs) (Bridler et al. 
2015, Paolini et al. 2017) may be effective for symptoms 
of anger, aggression, impulsivity and disruptive behav-
iours. Notwithstanding recent data demonstrate limited 
efficacy of psychotropic drugs (Stoffers-Winterling 
et al. 2020), especially on core EUPD symptoms such as 
chronic feelings of emptiness, identity disturbance and 
abandonment (Bozzatello et al. 2020).
METHODS AND OBJECTIVES
Individuals aged 18-65 with a diagnosis of EUPD, using 
the ICD-10 code of F60.30 and F60.31 (WHO, 1992) 
admitted to Lincolnshire NHS Foundation Trust (LPFT) 
inpatient services between 1st January 2017 and 31st 
December 2018 were included. Individuals with organic 
mental disorders and co-morbid schizophrenia-spec-
trum, major depressive disorder and bipolar affective 
disorders were excluded. This is a retrospective cohort 
examination, and data for the study were collected from 
patients’ medical records.
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Statistical analysis was conducted by the Mann-
Whitney-Wilcoxon test and Chi-squared test with 
Yates’s continuity correction.
The principal objective of this paper is to identify 
socio-demographics, clinical and service-delivery char-
acteristics of persons with EUPD. 
RESULTS
Of 1646 individuals (731 women, 915 men), 267 (16.2%) 
were initially identified with EUPD, ICD 10, F60.30/31. 
66 (24.7%) were excluded; 35 (13.1%) with co-morbid 
schizophrenia-spectrum disorders, and 31 (11.6%) with 
bipolar affective and recurrent depressive disorders. 
201 (12.2%); 133 women (66%) and 68 men (34%) were 
included to the observation. EUPD was significantly 
(P < .001) more frequent in women (18.6%); than in 
male patients (7.4%). Moreover, significantly (P < .001) 
more women (89.5%) than men (56%) were diag-
nosed with EUPD, borderline type. The impulsive type 
of the EUPD was in contrast diagnosed in only 10.5% 
of women but 44% of men.
When comparing the cohort of patients with 
EUPD with those without EUPD; EUPD patients were 
significantly (P < .001) younger (32.2 years) than those 
without EUPD (46 years). Moreover, individuals with 
EUPD had significantly (P < .001) more admissions 
(1.74) than those without EUPD (1.2 admission). The 
average length of stay (LOS) for patients with EUPD 
was 96 days and 85.6 days for those without EUPD.
Tab. 1. Demographic
Total (n=201) Women (n=133) Men (n=68)
Ethnicity
White British 198 (98.5%) 130 (98.0%) 68 (100.0%)
Another White 3 (1.5%) 3 (2.0%) 0
Family status
Single 136 (67.6%) 85 (64.0%) 51 (75.0%)
Married & cohabited 42 (20.8%) 34 (25.5%) 8 (11.7%)
Divorced & separated 21 (10.4%) 13 (10.0%) 9 (13.2%)
Widow 1 (0.5%) 1 (1.0%) 0.0%
Education
Basic 149 (74.0%) 96 (72.0%) 53 (78.0%)
Higher 31 (15.4%) 23 (17.3%) 8 (11.7%)
Academic 13 (6.4%) 10 (7.5%) 3 (4.4%)
Not stated 8 (4.0%) 4 (2.0%) 4 (6.0%)
Employment
Employed 48 (24.0%) 34 (25.6%) 14 (20.6%)
Unemployed 152 (75.6%) 98 (73.6%) 54 (79.4%)
Retired 1 (0.5%) 1 (0.75%) 0
Sexual orientation
Heterosexual 160 (79.6%) 103 (77.4%) 57 (83.8%)
LGBT 26 (13.0%) 21 (15.7%) 5 (7.3%)
Not stated 15 (7.5%) 9 (7.0%) 6 (9.0%)
Tab. 2. Hospital admission
Total (n=201) Women (n=133) Men (n=68)
Average number 
of admissions/two years 1.7 times 1.5 times 2.0 times
One admission 116 (57.7%) 82 (61.6%) 34 (50.0%)
Two admissions 48 (23.8%) 32 (24.0%) 16 (23.5%)
3≥ admissions 37 (18.4%) 19 (14.2%) 18 (26.4%)
LOS 96 days 123.3 days*P=0.005 42.8 days
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Patient demographics
Of 201, 198 (98.5%) patients were White British and 
three (1.5%) of other White origin. 67.6% were single, 
20.8% married (relatively more married women 
25.5%, than men 11.7%), 10.4% were separated and/or 
divorced, and one (0.5%) patient was widowed. With 
regards to education; 74.0%, had basic; 15.4% higher, 
and 6.4% academic education. In terms of employ-
ment; 24.4% were employed; and 75.6% were unem-
ployed. 79.5% identified themselves as heterosexuals; 
13.0% as lesbian, gay, bisexual or transsexual (LGBT), 
and 7.5% did not disclose their sexual orientation; 
table 1.
Admission and length of stay
The average number of admissions during the two-year 
period was 1.7. 57.7% of patients had one admission, 
23.7% two and 18.4% 3≥ admissions. The average LOS 
for the whole group was 96 days, nonetheless, women 
had significantly (P = 0.005) longer (123.3 days) admis-
sion than men (42.8 days); table 2.
Tab. 3. Self-harm, suicide attempts, attendances at the A&E, and suicide
Total (n=201) Women (n=133) Men (n=68)
Any suicide attempt 170 (84.5%) 113 (85%) 57 (84%)
One attempt 63 (31.3%) 41 (31%) 22 (32.5%)
Two attempts 31 (15.4%) 20 (15%) 11 (16%)
3≥ attempts 76 (37.8%) 52 (39%) 24 (35.3%)
Any attendance at A& E 168 (83.5%) 112 (84.2%) 56 (82.3%)
One attendance at A & E 68 (33.8%) 48 (36%) 20 (29.5%)
Two attendances at A & E 33 (16.4%) 21 (15.8%) 12 (17.6%)
3≥ attendances 67 (33.3%) 43 (32.3%) 24 (35.3%)
Death by suicide 4 (2.0%) 1 (0.75%) 3 (4.4%)
Overdose 3 (1.5%) 1 (0.75%) 2 (2.9%)
Hanging 1 (0.5%) 0 1 (1.5%)
Tab. 4. Early childhood trauma
Total (n=201) Women (n=133) Men (n=68)
Any abuse 179 (89.0%) 124 (93.2%) 55 (81.0%)
Physical abuse 52 (26.0%) 33 (25.0%) 19 (28.0%)
Sexual abuse 127 (63.2%) 91(68.4%)*P = 0.047 36 (53.0%)
Tab. 5. Psychiatric and medical co-morbidities
Total (n=201) Women (n=133) Men (n=68)
Physical co-morbidity 105 (52.2%) 72 (54.0%) 33 (48.5%)
1 psychiatric co-morbidity 142 (70.5%) 93 (70.0%) 49 (72.0%)
2 psychiatric co-morbidity 34 (17.0%) 23 (17.2%) 11 (16.2%)
Substance-use disorders 71 (35.3%) 38 (28.5%) 39 (57.3%)*P < .001
Alcoholism 30 (15.0%) 20 (15.0%) 10 (14.5%)
Polysubstance abuse 41 (20.4%) 18 (13.5%) 29 (42.6%)*P < .001
Neurotic & stress-related 
disorders 63 (31.3%) 47 (35.3%) 16 (23.5%)
Eating disorders 13 (6.5%) 12 (9.0%) 1 (1.5%)
LD 9 (4.5%) 8 (6.0%) 1 (1.5%)
ASD 4 (2.0%) 2 (1.5%) 2 (3.0%)
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Tab. 6. Pharmacotherapy
Total (n=201) Women (n=133) Men (n=68)
No medications used 5 (2.5%) 2 (1.5%) 3 (4.5%)
On medication 196 (97.5%) 131 (98.5%) 65 (95.5%)
Monotherapy 20 (10.0%) 13 (9.7%) 7 (10.3%)
Polypharmacy 176 (87.5%) 118 (88.7%) 58 (85.3%)
Two medications 37 (18.4%) 21 (15.7%) 16 (23.5%)
Three medications 43 (21.3%) 29 (21.8%) 14 (20.5%)
4≥ medications 96 (47.7%) 68 (51.0%) 28 (41.2%)
ANTIDEPRESSANTS
One AD 149 (74.0%) 102 (76.6%)*P = .026 47 (69.0%)
Two AD’s 21 (10.5%) 15 (11.0%) 6 (9.0%)
TCA 2 (1.0%) 2 (1.5%) 0 
SSRI’ 68 (34.0%) 40 (30.0%) 28 (41.2%)
SNRI’s 40 (20.0%) 34 (25.6%) *P = .002 6 (9.0%)
Mirtazapine 39 (19.4%) 26 (19.5%) 13 (19.0%)
Antipsychotics
One AP’s 157 (78.0%) 111 (83.5%) *P = 0.02 46 (67.6%)
Two AP’s 34 (17.0%) 25 (19%) 9 (13.2%)
FGA 20 (10.0%) 16 (12.0%) 4 (6.0%)
Haloperidol 6 (3.0%) 4 (3.0%) 2 (3.0%)
Trifluperazine 1 (0.5%) 1 (0.75%) 0
Zuclopenthixol 8 (4.0%) 8 (6.0%) 0
Chlorpromazine 5 (2.5%) 3 (2.2%) 2 (3.0%)
SGAs 137 (68.0%) 95 (71.4%) *P = 0.035 42 (61.8%)
Amisulpride 6 (3.0%) 4 (3.0%) 2 (3.0%)
Aripiprazole 33 (16.4%) 29 (22.0%)*P = .002 4 (6.0%)
Clozapine 3 (1.5%) 2 (1.5%) 0
Olanzapine 24 (12.0%) 13 (9.8%) 11 (16.2%)
Quetiapine 58 (29.0%) 43 (32.3%) 15 (22.0%)
Risperidone 14 (7.0%) 4 (3.0%) 10 (14.7%)
Depot AP’s 15 (7.5%) 10 (7.5%) 5 (7.3%)
Aripiprazole 2 (1.0%) 1 (0.75%) 1 (1.5%)
Paliperidone/Risperdal Consta 5 (2.5%) 0 3 (4.4%)
Haloperidol 1 (0.5%) 0 1 (1.5%)
Zuclopenthixol 7 (3.5%) 7 (5.2%) 0
ANXIOLYTICS 
One anxiolytic 115 (57.2%) 75 (56.4%) 40 (58.8%)
Two anxiolytics 34 (17.0%) 24 (18.0%) 10 (14.7%)
BDZ’s 82 (40.7%) 53(40.0%) 29 (42.6%)
Clonazepam 14 (7.0%) 12 (9.0%) 2 (3.0%)
Diazepam 33 (16.4%) 21 (15.8%) 12 (17.5%)
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History of self-harm and suicide
84.5% of patients had a history of self-harm and suicidal 
behaviours prior to their admission, which required 
treatment at the accident and emergency (A&E) depart-
ment. Of 201 patients, four (2.0%) died of suicide; drug 
overdose was the method of suicide in three patients, 
and strangulation in one patient; table 3. 
Early childhood trauma
Childhood trauma was reported by 179 (89.0%) 
patients; 26.0% reported physical abuse, whereas sexual 
abuse was reported by 63.2%, however, significantly 
(P = 0.047) more often by women (68.4%) than men 
(53.0%); table 4.
Clinical manifestation and co-morbidities
In terms of medical co-morbidities; 52.2% of patients 
had at least one medical co-morbidity. However, 70.5% 
have had at least one and 17.0% two axis-I psychiatric 
co-morbidities. Substance abuse was detected in 35.3% 
of all, but significantly (P < .001) more often in men 
(57.3%) than in women (28.5%). Similarly, multiple 
substance abuse was significantly (P = 0.001) more 
prevalent in men (42.6%) than in women (13.5%). 
Neurotic disorders were diagnosed in 31.3%, but more 
frequently in women (35%) than men (23.5%). Eating 
disorders were identified in 6.5% (9.0% of women, 1.5% 
of men), mild learning disabilities (LD) in 4.5% and 
autistic-spectrums disorders (ASD) in 2.0%; table 5.
Psychopharmacological management
Of 201 patients, 196 (97.5%) were prescribed a medica-
tion; 20 (10.0%) were on monotherapy, but 176 (87.5%) 
on polypharmacy; 37 (18.4%) were on two drugs, 43 
(21.3%) on three, and 96 (47.7%) on 4≥ medications 
concomitantly. More women (51.0%) than men (41.2%) 
used 4≥ medications.
In terms of antidepressants (AD’s), 74.0% of patients 
were on one, and 10.5% on two AD’s concomitantly. 
AD’s, were significantly (P=.26) more often prescribed 
to women (76.6%) than men (69.0%). SSRI’s were the 
most common AD’s prescribed in 34.0% of  patients, 
followed by SNRI’s (20.0%) and Mirtazapine (19.4%). 
Furthermore, SNRI’s were significantly (P  =  0.002) 
more often prescribed to women (25.6%) than men 
(9.0%). Tricyclic AD’s (TCA) plus SSRI’s or SNRI’s and 
Mirtazapine plus SSRI’s/SNRI’s were the most common 
combination of AD’s.
Similarly, 78% of all patients, but significantly 
(P  =  0.02) more women (83.5%) than men (67.5%) 
Total (n=201) Women (n=133) Men (n=68)
Lorazepam 35 (17.4%) 20 (15.0%) 15 (22.0%)
Pregabalin 33 (16.4%) 22 (16.5%) 11 (16.2%)
HYPNOTICS 
Any hypnotic drug 81 (40.3%) 53 (40.0%) 28 (41.2%)
BDZ’s hypnotics 5 (2.5%) 5 (4.0%) 0
Nitrazepam 4 (2.0%) 4 (3.0%) 0
Temazepam 1 (1.0%) 1(1.0%) 0
‘Z’ hypnotics 50 (25.0%) 29 (22.0%) 21 (31.0%)
Zopiclone 46 (23.0%) 25 (19.0%) 21 (31.0%)
Zolpidem 4 (2.0%) 4 (3.0%) 0
Other hypnotics 26 (13.0%) 19 (14.2%) 7 (10.3%)
Melatonin 2 (1.0%) 2 (1.5%) 0
Promethazine 24 (12.0%) 17 (13.0%) 7(10.3%)
MOOD STABILISERS 
Any mood stabiliser 52 (26.0%) 36 (27.0%) 16 (23.5%)
Lithium 4 (2.0%) 3 (2.2%) 1 (1.5%)
Antiepileptic mood stabilisers 48 (24%) 33 (25.0%) 15 (22.0%)
Carbamazepine 4 (2.0%) 2 (1.5%) 2 (3.0%)
Gabapentin 2 (1.0%) 1 (0.7%) 1 (1.5%)
Lamotrigine 29 (14.5%) 20 (15.0%) 9 (13.2%)
Topiramate 5 (2.5%) 5 (4.0%) 0
Valproate 8 (4.0%) 5 (4.0%) 3 (4.4%)
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were on AP’s. Moreover,17.0% of patients were on two 
AP’s. Whilst 10.0% used first generation antipsychotics 
(FGA), though, 68.0% were prescribed SGA’s, which 
were significantly (P = 0.035) more often utilised by 
women (71.4%) than men (62%). Amongst the SGAs, 
Quetiapine (29.0%), aripiprazole (16.4%) and olanzapine 
(12.0%) were the most frequently prescribed drugs; 
nonetheless, aripiprazole was significantly (P = .002) 
more prescribed to women (22.0%) than to men (6.0%). 
Additionally, 7.5% of the patients were prescribed depot 
AP’s; in 5.5% in combination with an oral AP’s.
In terms of anxiolytics, 57.2% were prescribed at least 
one and 17.4% two anxiolytic drugs. Benzodiazepines 
(BDZ’s) were the most common anxiolytics (40.7%) 
followed by pregabalin (16.4%). 
As far as the hypnotics are concerned, eighty-one 
patients (40.3%) were prescribed a hypnotic medica-
tion; of whom 50 (25.0%) were prescribed ‘z’-hypnotics 
(zolpidem and zopiclone), five (2.5%) BDZ’s hypnotics, 
and 26 (13.0%) other hypnotics.
With regards to the MS’s; 52 (26.0%) patients were 
prescribed MS’s; four (4.0%) were prescribed lithium 
and 48 (24.0%) antiepileptic drugs, mostly lamotrigine 
(14.5%); table 6.
Psychological interventions
47.7% of patients were provided psycho-education 
on their diagnosis and treatment alternatives; 43.2% 
received structured dialectical behavioural therapy 
(DBT).
DISCUSSION
In our study, of 1646 inpatients, 201 (12.2%) were 
diagnosed with EUPD, which correspond to findings 
of Doering, 2019 who reports the prevalence of EUPD 
among psychiatric inpatients between 9% and 14%. In 
our examination EUPD was significantly (P < .001) 
more prevalent in women (18.2%) than men (7.4%), 
and of 221 patients, 133 (66.0%) were female, which 
indicates a female to male ratio of 2:1. Furthermore, 
in our cohort, significantly (P < .001) more women 
(89.5%) than men (56.0%) were identified with EUPD, 
borderline type. Our results are comparable to results 
of Tadić et al. 2009 and Sher, et al. 2019, but dissimilar 
with outcomes of Oldham, 2005 estimating female 
to male ratio 3:1, or Koch et al, 2019 suggesting an even 
higher ratio of 4:1. It is assumed that EUPD is largely 
(75%) diagnosed in women, however, there is no 
significant difference in the lifetime prevalence of this 
disorder between men and women. This discrepancy 
of gender prevalence, therefore is anticipated to be 
resulting from the fact that women with EUPD are 
more likely to contact services and seek treatment than 
men (Canadian Agency for Drugs and Technologies in 
Health, 2017).
Our patient group consisted of mostly single, 
young individuals, with the average age of 32.2 years; 
unambiguously of White background. Our results 
are comparable with literature signifying people with 
EUPD consist of young single individuals of White 
background (Oldham, 2006, Yen et al. 2021).
The average number of admission for our patients 
was 1.7 admissions, and the average LOS was 96 days. 
Nonetheless, women had significantly (P = .005) longer 
(123.3 days) LOS than men (42.8 days). Data from 
Austria (Koch et al. 2019), Australia (Wong & Tye, 
2005), Germany (Kaess et al. 2017), and United States 
(Patel et al. 2019) unanimously associate the diagnosis 
EUPD with prolonged inpatient treatment, mainly 
because of high risk of suicide. 84.5% of our subjects 
had a history of self-harm and/or suicide attempts 
prior to their admission. This is almost identical with 
the findings of Soloff et al. 2002 who reported suicidal 
behaviours in 84% of patients with EUPD. Likewise, 
our outcomes are consistent with previous findings 
of Hull, et al. 1996, suggesting suicidal behaviours were 
the most common triggers leading to patients’ admis-
sion. Opinions regarding hospitalisation of people with 
EUPD vary amongst professionals. Nonetheless, the 
consensus is that hospital resources should be used 
to carry out specific aspects of treatment that cannot 
be provided in the community (Paris, 2002, Bateman 
& Fonagy, 1999). Improved access to psychological 
therapies can reduce inpatient admissions, and fewer 
prescriptions for antidepressants, resulting in an esti-
mated 9%-53% reductions in short, medium and long-
term costs. Furthermore, if patients with personality 
disorders are treated in the community, i.e. under the 
crisis and home treatment teams instead of hospital, 
this would have reduced the LOS and hospital cost up 
to £600 per admission (McCrone et al. 2008).
We have found widespread co-morbidities amongst 
our patients; 70.5% had at least one and 17% two Axis-I 
co-morbidities. In a similar study, Timäus et al. 2019 
reported that 79.3% of the EUPD inpatients had at least 
one, 46.0% two and 28.7% three or more psychiatric 
co-morbidities. There is a body of evidence (Wetterborg 
et al. 2015) reporting a prevalent co-morbidity amongst 
people with EUPD, and individuals with EUPD being 
twice as likely to receive a diagnosis of three or more 
Axis-I disorders, compared with those without EUPD 
(Zimmerman & Mattia, 1999). Substance abuse was the 
most common co-morbidity detected in 35.0% of our 
patients, but significantly (P < .001) more often in 
men (57.0%) than in women (28.5%). Likewise, poly-
substance abuse was significantly (P = 0.001) more 
widespread in men (42.6%) than in women (13.5%). 
Evidence indicate higher levels of alcohol and drugs 
abuse in individuals with EUPD (Tadić et al. 2009, 
Sher et al. 2019). Neurotic and stress-related mental 
disorders were observed in 31.3% of all, but relatively 
more in women (35%) than men (23.5%). Our find-
ings mirror previous research (Timäus et al. 2019, 
Tadić et al. 2009, McCormick et al. 2007) reporting 
stress-related disorders are amongst the most common 
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co-morbidities found in people with EUPD. Eating 
disorders were identified in 9% of women and 1.5% 
of men. Tadić et al. 2009 reported eating disorders in 
13% of their sample. 4.5% of our subjects had mild 
LD. Data from the Netherlands (Wieland et al. 2015) 
reported higher frequency of personality disorders in 
people with borderline intellectual functioning. ASD 
were detected in 2.0% of our patients, which is rela-
tively lower in comparison to literature that estimates 
ASD in approximately 10% of people with EUPD 
(Bringmann & Maidman, 2019). Besides, evidence 
suggests that EUPD patients have elevated autistic 
traits, suggesting an overlap between EUPD and ASD 
(Dudas et al. 2017). The presence of ASD traits has also 
been associated with higher suicidality in patients with 
EUPD (Chabrol & Raynal, 2018). A recent study from 
the UK (Fok et al. 2019) examining records of 7677 
individuals with personality disorders concluded that 
people with personality disorders, compared to general 
population had an increased admission rate for several 
conditions, including cardiovascular, respirator, diges-
tive, nervous and musculoskeletal system disorders. 
The extensive co-morbidity among individuals with 
EUPD results in a substantial increase and extensive 
use of services (Cailhol et al. 2015, Bender et al. 2006) 
resulting in higher total healthcare costs (Rendu et al. 
2002) 46 compared with people with other personality 
disorders; major depression, or general anxiety disorder 
(Soeteman et al. 2008).
Almost 90% of our patients reported a history 
of  childhood trauma, whereas the history of sexual 
abuse was reported, significantly (P = .047) more by 
women (68.4%) than men (53.0%). Childhood sexual 
abuse has been reported in 40% to 70% of inpatients 
with EUPD (Zanarini et al. 2006). The history of child-
hood sexual abuse is strongly associated with the higher 
risk of suicidal behaviours, increased hostility, severity 
of the illness and feelings of hopelessness (Brodsky et al. 
1997, Soloff et al. 2002, Yen et al. 2021). Additionally, the 
history of childhood abuse has been linked with a 5-fold 
increase in the rate of lifetime suicide attempts relative 
to individuals with no history of abuse (Kaplan et al. 
2016). In a systematic review of 37 studies, with a total 
of 253719 participants, Hughes et al. 2017 demonstrated 
that individuals with a history of  adverse childhood 
experiences (ACEs) were at higher risk of mental health 
problems, compared with individuals with no ACEs. 
Similarly, a meta-analysis of 97 studies comparing 
persons with EUPD to individuals with other mental 
disorders and controls revealed that people with EUPD 
were 3.15 times more likely to report ACEs than other 
psychiatric groups, and 13.9 times more likely to report 
ACEs than non-clinical controls (Porter et al. 2020).
In our study, 4.4% of men, and 0.75% of women 
died because of suicide. In a 24-year prospective study 
of 290 patients with EUPD and 72 non-EUPD cohort, 
Temes et al. 2019 reported a total of 5.9% of borderline 
patients and 1.4% of control subjects died by suicide. 
Risk factor for completed suicide in people with EUPD 
include older age, previous suicide attempts, co-morbid 
alcoholism or substance abuse (Brodsky et al. 1997), 
and interpersonal problems (Gvion & Levi-Belz, 2018). 
Moreover, it has been reported that men with EUPD 
are at higher risk of dying by suicide than women (Sher 
et al. 2019). 
In our study, 87.5% of patients were on polyphar-
macy; 18.4% were on ≥ 2 drugs, 21.3% on ≥ 3 drugs 
and 47.7% on ≥ 4 drugs. Our results are in line with 
literature (Aguglia et al. 2019) reporting a widespread 
polypharmacy among people with EUPD. A study from 
Italy (Paolini et al. 2017) reported 83.5% of their inpa-
tients with EUPD were on polypharmacy. Data from 
the European Drug Safety Project (Bridler et al. 2015) 
analysing information on medication in 2195 inpatients 
with EUPD found that 90% received at least one, 80% ≥ 
2 and 54% ≥ 3 psychotropic medications concomitantly. 
In a naturalistic study of 226 individuals with EUPD 
Pascual et al. 2010 reported that 97.4% of the patients 
were on medications; 56% taking ≥ 3 drugs and 30% ≥ 
4 drugs. 
In our study 74.0% of patients were on ADs, and 
10.5% on two AD’s. Moreover, AD’s were significantly 
(P = .02) more often prescribed to women (76.6%) than 
men (69.0%). Our findings are almost identical with 
the findings of Bridler et al. 2015 who reported 70% 
of  patients with EUPD were medicated with AD’s. In 
our study, SSRI’s (34%) were the most common group 
of AD’, followed by SNRI’s (20%) and mirtazapine (25%). 
Furthermore, SNRI’s were significantly (P = 0.002) more 
often prescribed to female patients (25.6%) than their 
male counterparts (9.0%). In similar study, Timäus et al. 
2019 reported SSRI’s (52.3%) being the most frequent 
medication group, followed by mirtazapine (31.8%) and 
TCA’s (13.6%). 
Correspondingly, 78.0% of patients were on AP’s, 
but significantly (P = 0.02) more women (83.5%) than 
men (67.5%). Our outcomes are comparable with the 
findings of Bridler et al. 2015 who reported AP’s use 
in 70% and Paolini et al. 2017 in 78.7% of individuals 
with EUPD. We found Quetiapine (29.0%), aripipra-
zole (16.4%) and olanzapine (12.0%) the most common 
drugs used by our subjects. Nevertheless, in our study, 
aripiprazole was significantly (P = .002) more often 
prescribed to women (22.0%) than to men (6.0%). 
A study from Italy, Aguglia et al. 2019 reported a similar 
trend, indicating olanzapine, quetiapine and aripipra-
zole being the most common antipsychotics prescribed 
for people with EUPD. Similarly, a study from Austria 
(Riffer, et al. 2019) found quetiapine the most common 
SGA prescribed in EUPD. Strong evidence supporting 
use of SGA in EUPD is lacking (Wasylyshen & Williams, 
2016), although they have proven to be efficacious in 
managing anger, aggression (Tadić et al. 2009, Sher et al. 
2019) and in reducing cognitive-perceptual symptoms 
(Vita et al. 2011). Amongst SGA aripiprazole seems 
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to be having a much larger effect on anger than another 
AP’s (Mercer et al. 2009).
7.5% of our patients were prescribed a depot AP’s; 
5.5% in combination with another AP’s. Evidence 
on use and efficacy of long acting AP’s in people 
with EUPD is vague. Though, in a six-month small 
study of  12 patients with severe EUPD Díaz-Marsá 
et al. 2008 report a significant clinical and functional 
improvement in patients. Likewise, in a 12-week study 
of 16  patients with EUPD treated with paliperidone 
palmitate Palomares et al. 2015 reported a significant 
decrease in impulsivity, disruptive behaviour and 
improvement in patients’ psychosocial functioning. 
In another six-month study of 49 patients with EUPD 
treated with long acting risperidone Carrasco et al. 2012 
reported a significant decrease in symptoms of anxiety 
and aggression as well as improvement in patients’ level 
of psychosocial functioning. In a case-study of a 40-year 
old patient suffering from EUPD with co-morbid 
bipolar disorder, and substance abuse, Martínez and 
Caballero, 2017 reported the patient was successfully 
treated with aripiprazole long acting injection. 
Likewise, 57.2% of the patients in our study were 
on at least one, and 17% on two anxiolytic drugs. 
Furthermore, 40% used hypnotic medications. Use 
of anxiolytics has been reported in about 30% of inpa-
tients with EUPD (Bridler et al. 2015, Bender et al. 
2006), nonetheless, a study from Italy (Paolini et al. 
2017) reported that 85.2% of their inpatients were 
prescribed benzodiazepine anxiolytics and hypnotics. 
26.0% of our patients were also on MS’s; 24.0% on 
anticonvulsants and 2.0% on lithium. Corresponding 
to our results, Bridler et al. 2015 reported use of anti-
convulsants in 33% and lithium in 4% of people with 
EUPD. Likewise, Bender et al. 2006 reported use of MS’s 
in 27% of their subjects with EUPD. Nonetheless, 
Paolini et al. 2017 stated higher, 70% use of MS’s in 
their inpatients with EUPD. Despite their frequent use, 
there are opposing interpretations on efficacy of MS’s in 
the management of EUPD. Earlier evidence, supported 
use of MS’s for management of anger and depres-
sive symptomatology. However, Hancock-Johnson et 
al. 2017 in a systematic review of 15 pharmacological 
studies challenged the efficacy of MS’s implying there is 
little evidence to support use of these drugs in patients 
with EUPD. Furthermore, Crawford et al. 2018 in the 
RCT of up to 200 mg of lamotrigine per day compared 
to placebo in a cohort of 196 individuals with EUPD 
concluded that lamotrigine was not clinically effective. 
Moreover, recent evaluation of seven RCT studies found 
no effect of lamotrigine, a common MS prescribed 
to people with EUPD (Stoffers-Winterling et al. 2020). 
Whilst most of our patients received pharmaco-
therapy, only 43.2% received structured DBT. This 
could be associated with several factors; firstly, most 
patients with EUPD struggle to engage with psycholog-
ical interventions and view pharmacological interven-
tions as more effective and rather a ‘quick fix’. Secondly, 
from the service-provider point of view, most psycholo-
gists would refuse to accept a patient with EUPD who 
is suicidal or uses alcohol or other substances. Besides, 
limited psychological therapies could reflect inadequate 
services. Psychotherapies are the treatment of choice for 
people with EUPD (NICE, 2009, Verheul & Herbrink, 
2007). Psychodynamic psychological interventions 
such as mentalisation-based therapy (MBT) and trans-
ference-focused therapy (TFT) and cognitive-behav-
ioural based therapies such as dialectical–based therapy 
(DBT) and scheme-focused therapies (SFT) have been 
shown to be effective, particularly, in reducing the self-
destructive behaviour (Zanarini, 2009). However, recent 
opinions on the efficacy of psychological therapies are 
not as optimistic. Stoffers, et al. 2012 in a  systematic 
review of twenty-eight studies involving a total of 1804 
participants with EUPD reported psychotherapies, 
such as DBT, MBT and TFT beneficial, nonetheless, 
they concluded none of the therapies had a robust 
evidence base, and raised concerns about the quality 
of the individual studies. In a literature review of sixteen 
randomised clinical trials, analysing effects of DBT, 
SFT cognitive behavioural therapy (CBT) and manual-
assisted cognitive therapy, Marques et al. 2017 reported 
that from all the above psychological interventions, 
especially DBT and SFT showed beneficial effects by 
reducing the severity and frequency of self-harm, and 
by improving the overall social, interpersonal and global 
functioning. In a similar literature review of  twenty 
studies with 1375 participants, Oud et al. 2018 concluded 
that DBT and MBT and TFT compared to treatment as 
usual (TAU) were effective in reducing overall symp-
tomatology and severity of EUPD, however, their effects 
were small to  medium. Similarly, Cristea et  al. 2017 
in a Cochrane review of thirty-three trials with 2256 
participants, come to assumption that psychothera-
pies, especially DBT and psychodynamic approaches 
were effective for EUPD symptoms, nonetheless, these 
effects were small, inflated by risk of bias and publica-
tion bias, and predominantly unstable in follow-up. In 
a most recent Cochrane review of 75 RCT with 4507 
participants, comparing sixteen different psychological 
interventions with TAU, Storebø et al. 2020, found no 
evidence of a difference in effects estimates between 
the different types of psychological therapies. Though, 
compared to TAU, DBT was more effective in the reduc-
tion of EUPD severity, self-harm and psychosocial func-
tioning and, for MBT, more efficacious on self-harm, 
suicidality and depression. Nonetheless, the authors 
of  the study expressed an opinion that these findings 
were based on low quality evidence.
CONCLUSIONS
People with EUPD tend to represent one of the most 
challenging groups of patients, with multiple needs and 
complex presentation. Polypharmacy and co-morbid-
ities are very widespread. They are one of the most 
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recurrent clients of emergency services, requiring 
urgent medical care. 
No psychotropic drug is specifically licensed for 
EUPD, and the choice of medications is largely based 
upon the predominant axis-I comorbid condition17. 
Opinion from the United States (APA, 2001, APA, 
2005) and Europe (Lieb et al. 2010) recommend 
psychotherapy as the principal treatment for this 
disorder, nonetheless, they also support a symptom-
targeted pharmacotherapy. The NICE agrees with the 
use of psychotherapy, but is against the use of psycho-
tropic medication for individual symptoms of EUPD. In 
addition, where there are depressive or psychotic symp-
toms, or affective instability, that fall short of diagnostic 
criteria for mental disorder, the use of psychotropic 
drugs is largely ‘off-label’. Prescribing off-label places 
additional responsibilities on the prescriber and may 
increase liability if there are adverse effects. The Royal 
College of Psychiatrists recommends that the patient be 
informed that the drug prescribed is not licensed for 
the indication for which it is being used, and the reason 
for its use and potential side effects fully explained 
(Baldwin & Kosky, 2007). 
There are several factors why individuals with 
EUPD are prescribed multiple medications despite 
their limited evidence. One of the major issues is the 
fact that patients with EUPD have several crises, and 
each crisis can be very distressing. At times of crisis, few 
patients would engage in psychotherapies, and hence 
both patients and professionals are left with no other 
alternative than to use pharmacotherapy. Hence each 
time they are presented at the crisis assessment settings 
or admitted to hospital; they are prescribed a new medi-
cation. The most likely reason for this seems to be that 
patients and their relatives but also prescribers assume 
that previous recommended medicines were ineffec-
tive; hence, to enhance their efficacy or/and prevent 
further deterioration, they prescribe an additional 
drug. Besides, there are many clinicians, who believe 
pharmacological therapies are effective and should be 
prescribed for individual symptoms of EUPD. On the 
contrary there are clinicians prescribing medication not 
because they are convinced of their efficacy, nonethe-
less feel pressurised by patients and their families as 
they fear complaints and negative criticism. Likewise, 
lack of specialised services for people with personality 
disorders, and the absence of the availability of psycho-
logical services is another factor for polypharmacy. 
The introduction of specialised services for people 
with EUPD that will offer individualised and trauma-
focused psychotherapies is one of the most effective 
ways to tackle the issue of medication over-prescrip-
tion. Besides it will also lead to effective management 
these individuals in the community, reduce their length 
of admission and overall improve the quality of life for 
people with personality disorders. 
In the light of existing practice and evidence from 
research, we believe current NICE guidance of EUPD 
is out of date and not fit for purpose. The future NICE 
guidance should revise the pharmacotherapy of EUPD 
and should consider symptom-targeted pharmaco-
therapy. Moreover, the new guidance would also need 
to expand beyond DBT and should consider other 
methods of psychological therapies such as MBT, TFT, 
SFT and eye-movement desensitization and repro-
cessing therapy. 
We believe the term EUPD causes stigma to patients, 
does not reflect the true nature, gravity and psychopa-
thology of this illness. The is a large body of evidence 
demonstrating that people with EUPD experience 
stigma because of their illness, which in some cases 
limits their access to health services, quality of their 
care, and their potential to achieve optimal health 
and well-being (Klein, et al. 2021). The term border-
line personality disorder is out of date, incorrect and 
too simplistic to reflect the true nature, gravity and 
psychopathology of this compounded syndrome. 
Instead, enduring personality changes, ICD 10 F62, or 
tardive and complex PTSD, should be considered. We 
warmly welcome the ICD 11 diagnosis of Complex 
posttraumatic disorder, 6B41 that better captures symp-
toms of the EUPD, is not stigmatising, and most of all 
considers the traumatic nature of this condition (WHO, 
2020).
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